help button home button Am J Pathol Angiogenesis Foundation
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/ajpath.2009.080967 on June 4, 2009

Published online before print June 4, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajpath.2009.080967v1
175/1/235    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, R.
Right arrow Articles by Martin, P. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, R.
Right arrow Articles by Martin, P. T.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
*Substance via MeSH
Related Collections
Right arrowRelated Article
(American Journal of Pathology. 2009;175:235-247.)
© 2009 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2009.080967

Overexpression of Galgt2 Reduces Dystrophic Pathology in the Skeletal Muscles of Alpha Sarcoglycan-Deficient Mice

Rui Xu, Sarah DeVries, Marybeth Camboni and Paul T. Martin

From the Center for Gene Therapy, the Departments of Pediatrics, Physiology and Cell Biology, Ohio State University College of Medicine, Columbus, Ohio

Recent studies have shown that a number of genes that are not mutated in various forms of muscular dystrophy may serve as surrogates to protect skeletal myofibers from injury. One such gene is Galgt2, which is also called cytotoxic T cell GalNAc transferase in mice. In this study, we show that Galgt2 overexpression reduces the development of dystrophic pathology in the skeletal muscles of mice lacking {alpha} sarcoglycan (Sgca), a mouse model for limb girdle muscular dystrophy 2D. Galgt2 transgenic Sgca–/– mice showed reduced levels of myofiber damage, as evidenced by i) normal levels of serum creatine kinase activity, ii) a lack of Evans blue dye uptake into myofibers, iii) normal levels of mouse locomotor activity, and iv) near normal percentages of myofibers with centrally located nuclei. In addition, the overexpression of Galgt2 in the early postnatal period using an adeno-associated virus gene therapy vector protected Sgca–/– myofibers from damage, as observed using histopathology measurements. Galgt2 transgenic Sgca–/– mice also had increased levels of glycosylation of {alpha} dystroglycan with the CT carbohydrate, but showed no up-regulation of β, {gamma}, {delta}, or {epsilon} sarcoglycan. These data, coupled with results from our previous studies, show that Galgt2 has therapeutic effects in three distinct forms of muscular dystrophy and may, therefore, have a broad spectrum of therapeutic potential for the treatment of various myopathies.


Related Article

This Month in AJP
Am. J. Pathol. 2009 175: 1-2. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Sci Transl MedHome page
K. Chandrasekharan, J. H. Yoon, Y. Xu, S. deVries, M. Camboni, P. M. L. Janssen, A. Varki, and P. T. Martin
A Human-Specific Deletion in Mouse Cmah Increases Disease Severity in the mdx Model of Duchenne Muscular Dystrophy
Science Translational Medicine, July 28, 2010; 2(42): 42ra54 - 42ra54.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Society for Investigative Pathology.